SummaryRMgm-5093
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 34673764 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Hart KJ, Lindner SE |
Name Group/Department | Department of Biochemistry and Molecular Biology, The Huck Center for Malaria Research |
Name Institute | Pennsylvania State University |
City | Pennsylvania |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5093 |
Principal name | pynot1-g(−) |
Alternative name | py17x_0945600-null parasites |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | No significant asexual blood-stage growth defects were observed for py17x_0945600-null parasites until late in the blood-stage infection (day 10). At this point, there was a small but statistically significant decrease in peak parasitemia with a concomitant earlier time to parasite clearance |
Gametocyte/Gamete | Evidence is presented for a slight increase in gametocyte production; no male gamete production (exflagellation); female gametes infertile (i.e. were unable to produce developing zygotes) |
Fertilization and ookinete | No ookinete or oocyst production |
Oocyst | No ookinete or oocyst production |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Plasmodium’s NOT1 paralogues localize to cytosolic puncta: 'To determine if the 2 paralogues of NOT1 are used at different points in the Plasmodium life cycle, we used conventional reverse genetics approaches to append a C-terminal GFP tag to each NOT1 paralogue in P. yoelii and assessed their expression and localization. Both NOT1 paralogues were expressed and localized at the same times in the life cycle, and the expression pattern for PyNOT1 and PyNOT1-G is cytosolic and at least partially punctate. This is consistent with the localization of other members of the CAF1/CCR4/NOT complex in Plasmodium, model eukaryotes, and human cells. Of note, the NOT1 paralogues were expressed in both asexual and sexual blood stage parasites with a nonuniform, cytosolic distribution with some puncta visible. Both paralogous proteins were expressed in mosquito stage parasites, with localization shifting from a cytosolic diffuse pattern in oocysts, to a more nucleus-proximal pattern in oocyst sporozoites, and, finally, to a more apical pattern in salivary gland sporozoites. No expression of either protein was observed in mid- or late-liver stage parasites. Together, these expression and staining patterns match what is commonly seen for members of the CAF1/CCR4/NOT complex in other eukaryotes, as well as what we observed previously in P. yoelii with 2 other members of this complex: CAF1 and CCR4-1 [21]. Coupled with proteomic data showing their association with CCR4-1, this strongly indicates that these NOT1 paralogues are resident members of the CAF1/CCR4/NOT complex in P. yoelii. Evidence is presented that: |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_0945600 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1103800 | ||||||||||||||||||||||||
Gene product | CCR4-NOT transcription complex subunit 1, putative | ||||||||||||||||||||||||
Gene product: Alternative name | NOT1-G | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | Transgenic P. yoelii 17XNL strain parasites were produced through conventional reverse genetics approaches using 2 homology arms that are specific to the targeted gene. Homology arms were PCR amplified from wild-type genomic DNA, were combined into a single PCR amplicon by SOE PCR, were inserted into pCR-Blunt for sequencing, and were finally inserted into a pDEF plasmid for use in P. yoelii parasites. Plasmids used for gene deletion were based upon pSL0444, which replaces the gene sequences with a GFPmut2 expression cassette, a HsDHFR expression cassette, and the plasmid backbone. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |